Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : AiCuris
Deal Size : Undisclosed
Deal Type : Collaboration
AiCuris collaborates with myTomorrows
Details : The companies are collaborating to develop an Early Access Program for pritelivir, for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 02, 2020
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : AiCuris
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible . Company is now preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable